Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Investigational New DrugsOpen Access

Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center study

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXian LiXZXinyi ZhuXXXibin Xiao

Discussion

Loading...

Member takes

Overview

Single-center retrospective study shows favorable survival outcomes in frail AML patients treated with reduced-dose venetoclax and azacitidine.

Key Points

  • All patients achieved complete remission, with median OS exceeding 24.6 months in frail individuals.
  • Elevated trough venetoclax concentrations confirmed adequate drug exposure, averaging 487.7 ng/mL.
  • Adverse-risk patients had a 50% survival rate beyond 21.8 months, indicating potential benefits of reduced dosing.
  • Safety profile showed lower rates of hematologic toxicities compared to historical full-dose venetoclax data.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/68bb46c96d6d5674bccff221https://doi.org/10.1007/s10637-025-01579-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China2026
  2. 2Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience2024 · 4 citations
  3. 3Short-term Group Venetoclax Combined with Azacitidine for Treating Newly Diagnosed Elderly Acute Myeloid Leukemia: A Retrospective Study2024
  4. 4Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial2025 · 1 citations
  5. 5Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan2026